Exact Mass: 507.3563

Exact Mass Matches: 507.3563

Found 175 metabolites which its exact mass value is equals to given mass value 507.3563, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Gymnodimine

5-[(2E)-19-hydroxy-2,15,18,24-tetramethyl-25-oxa-7-azatetracyclo[20.2.1.0⁶,¹¹.0¹¹,¹⁶]pentacosa-2,6,14,17-tetraen-14-yl]-3-methyl-2,5-dihydrofuran-2-one

C32H45NO4 (507.3348)


Gymnodimine is found in mollusks. Gymnodimine is isolated from New Zealand oysters (Tiostrea chilensis) and the dinoflagellate Gymnodinium cf. mikimotoi. Isolated from New Zealand oysters (Tiostrea chilensis) and the dinoflagellate Gymnodinium cf. mikimotoi. Gymnodimine is found in mollusks.

   

LysoPE(0:0/20:1(11Z))

(2-aminoethoxy)[(2R)-3-hydroxy-2-[(11Z)-icos-11-enoyloxy]propoxy]phosphinic acid

C25H50NO7P (507.3325)


LysoPE(0:0/20:1(11Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/20:1(11Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

   

LysoPE(20:1(11Z)/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-[(11Z)-icos-11-enoyloxy]propoxy]phosphinic acid

C25H50NO7P (507.3325)


LysoPE(20:1(11Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(20:1(11Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

   

LysoPC(P-18:0/0:0)

(2-{[(2R)-2-hydroxy-3-[(1Z)-octadec-1-en-1-yloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


LysoPC(P-18:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(P-18:0), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. LysoPC(P-18:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(P-18:0), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

   

13-(3-Methyl-5-pentylfuran-2-yl)tridecanoylcarnitine

3-{[13-(3-methyl-5-pentylfuran-2-yl)tridecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C30H53NO5 (507.3924)


13-(3-methyl-5-pentylfuran-2-yl)tridecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-(3-methyl-5-pentylfuran-2-yl)tridecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-(3-methyl-5-pentylfuran-2-yl)tridecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 13-(3-methyl-5-pentylfuran-2-yl)tridecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(5-Hexyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine

3-{[11-(5-hexyl-3,4-dimethylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C30H53NO5 (507.3924)


11-(5-hexyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(5-hexyl-3,4-dimethylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(5-hexyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 11-(5-hexyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(5-Heptyl-3-methylfuran-2-yl)undecanoylcarnitine

3-{[11-(5-heptyl-3-methylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C30H53NO5 (507.3924)


11-(5-heptyl-3-methylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(5-heptyl-3-methylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(5-heptyl-3-methylfuran-2-yl)undecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 11-(5-heptyl-3-methylfuran-2-yl)undecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-(3,4-Dimethyl-5-pentylfuran-2-yl)dodecanoylcarnitine

3-{[12-(3,4-dimethyl-5-pentylfuran-2-yl)dodecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C30H53NO5 (507.3924)


12-(3,4-dimethyl-5-pentylfuran-2-yl)dodecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-(3,4-dimethyl-5-pentylfuran-2-yl)dodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-(3,4-dimethyl-5-pentylfuran-2-yl)dodecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 12-(3,4-dimethyl-5-pentylfuran-2-yl)dodecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Cholylvaline

3-methyl-2-(4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)butanoic acid

C29H49NO6 (507.356)


Cholylvaline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Cholylvaline consists of the bile acid cholic acid conjugated to the amino acid Valine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Cholylvaline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Cholylvaline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Chenodeoxycholylaspartic acid

2-[(4-{5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-14-yl}-1-hydroxypentylidene)amino]butanedioate

C28H45NO7 (507.3196)


Chenodeoxycholylaspartic acid belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylaspartic acid consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Aspartic acid conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylaspartic acid, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylaspartic acid appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

(1S,10S,21R)-7-Ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

(1S,10S,21R)-7-Ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

C28H45NO7 (507.3196)


   

Phosphatidylethanolamine lyso 20:1

Phosphatidylethanolamine lyso 20:1

C25H50NO7P (507.3325)


   

Phosphatidylcholine lyso 17:1

Phosphatidylcholine lyso 17:1

C25H50NO7P (507.3325)


   

amphiasterin D2

amphiasterin D2

C29H49NO6 (507.356)


   

Me ester-Indanomycin

Me ester-Indanomycin

C32H45NO4 (507.3348)


   
   

14-isobutyrylnudicaulidine

14-isobutyrylnudicaulidine

C28H45NO7 (507.3196)


   
   

Valine conjugated cholic acid

Valine conjugated cholic acid

C29H49NO6 (507.356)


   

Aspartate conjugated chenodeoxycholic acid

Aspartate conjugated chenodeoxycholic acid

C28H45NO7 (507.3196)


   

((4R)-4-((3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)valine

"((4R)-4-((3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)valine"

C29H49NO6 (507.356)


   

LPC(17:1)

1-(10Z-heptadecenoyl)-sn-glycero-3-phosphocholine

C25H50NO7P (507.3325)


   

PC(O-18:1/0:0)[S]

3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, [S-(Z)]-

C26H54NO6P (507.3689)


   

PC(O-18:1/0:0)[U]

3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (Z)-

C26H54NO6P (507.3689)


   

PC(O-18:1/0:0)

3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, [R-(Z)]-

C26H54NO6P (507.3689)


   

PC(P-18:0/0:0)

3,5,9-Trioxa-4-phosphaheptacos-10-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, [R-(Z)]-

C26H54NO6P (507.3689)


   

LPE(20:1)

1-Eicosenoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine

C25H50NO7P (507.3325)


   

PC(17:1(9Z)/0:0)

1-(9Z-heptadecenoyl)-glycero-3-phosphocholine

C25H50NO7P (507.3325)


   

LysoPE(20:1/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-[(11Z)-icos-11-enoyloxy]propoxy]phosphinic acid

C25H50NO7P (507.3325)


   

LPC 17:1

1-(10Z-heptadecenoyl)-sn-glycero-3-phosphocholine

C25H50NO7P (507.3325)


   

LysoPC O-18:1

1-(11Z-octadecenyl)-sn-glycero-3-phosphocholine

C26H54NO6P (507.3689)


   

LPE 20:1

2-(11Z-eicosenoyl)-sn-glycero-3-phosphoethanolamine

C25H50NO7P (507.3325)


   

Elacytarabine

Elacytarabine

C27H45N3O6 (507.3308)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.

   

5-{19-Hydroxy-2,15,18,24-tetramethyl-25-oxa-7-azatetracyclo[20.2.1.0^{6,11}.0^{11,16}]pentacosa-2,6,14,17-tetraen-14-yl}-3-methyl-2,5-dihydrofuran-2-one

5-{19-Hydroxy-2,15,18,24-tetramethyl-25-oxa-7-azatetracyclo[20.2.1.0^{6,11}.0^{11,16}]pentacosa-2,6,14,17-tetraen-14-yl}-3-methyl-2,5-dihydrofuran-2-one

C32H45NO4 (507.3348)


   

13-(3-Methyl-5-pentylfuran-2-yl)tridecanoylcarnitine

13-(3-Methyl-5-pentylfuran-2-yl)tridecanoylcarnitine

C30H53NO5 (507.3924)


   

11-(5-Heptyl-3-methylfuran-2-yl)undecanoylcarnitine

11-(5-Heptyl-3-methylfuran-2-yl)undecanoylcarnitine

C30H53NO5 (507.3924)


   

11-(5-Hexyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine

11-(5-Hexyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine

C30H53NO5 (507.3924)


   

12-(3,4-Dimethyl-5-pentylfuran-2-yl)dodecanoylcarnitine

12-(3,4-Dimethyl-5-pentylfuran-2-yl)dodecanoylcarnitine

C30H53NO5 (507.3924)


   

Chenodeoxycholylaspartic acid

Chenodeoxycholylaspartic acid

C28H45NO7 (507.3196)


   

3-cyclohexyl-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

3-cyclohexyl-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

3-cyclohexyl-1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

3-cyclohexyl-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

3-cyclohexyl-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

3-cyclohexyl-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

3-cyclohexyl-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

3-cyclohexyl-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea

C30H41N3O4 (507.3097)


   

1-(1E-octadecenyl)-sn-glycero-3-phosphocholine

1-(1E-octadecenyl)-sn-glycero-3-phosphocholine

C26H54NO6P (507.3689)


   

[2-hydroxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H54NO6P (507.3689)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-icos-11-enoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-icos-11-enoate

C25H50NO7P (507.3325)


   
   

NAGly 11:0/17:2

NAGly 11:0/17:2

C30H53NO5 (507.3924)


   

NAGly 12:0/16:2

NAGly 12:0/16:2

C30H53NO5 (507.3924)


   

NAGly 18:2/10:0

NAGly 18:2/10:0

C30H53NO5 (507.3924)


   

NAGly 10:0/18:2

NAGly 10:0/18:2

C30H53NO5 (507.3924)


   

NAGly 13:1/15:1

NAGly 13:1/15:1

C30H53NO5 (507.3924)


   

NAGly 15:1/13:1

NAGly 15:1/13:1

C30H53NO5 (507.3924)


   

NAGly 14:1/14:1

NAGly 14:1/14:1

C30H53NO5 (507.3924)


   

NAGly 16:2/12:0

NAGly 16:2/12:0

C30H53NO5 (507.3924)


   

NAGly 17:2/11:0

NAGly 17:2/11:0

C30H53NO5 (507.3924)


   

2-aminoethyl [3-[(Z)-henicos-11-enoxy]-2-hydroxypropyl] hydrogen phosphate

2-aminoethyl [3-[(Z)-henicos-11-enoxy]-2-hydroxypropyl] hydrogen phosphate

C26H54NO6P (507.3689)


   

[3-[(Z)-heptadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-[(Z)-heptadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C25H50NO7P (507.3325)


   

[2-butanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-butanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C25H50NO7P (507.3325)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] heptanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] heptanoate

C25H50NO7P (507.3325)


   

3-Hydroxy-2-(2-hydroxypentadecanoylamino)undecane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxypentadecanoylamino)undecane-1-sulfonic acid

C26H53NO6S (507.3593)


   

3-Hydroxy-2-(2-hydroxytridecanoylamino)tridecane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxytridecanoylamino)tridecane-1-sulfonic acid

C26H53NO6S (507.3593)


   

3-Hydroxy-2-(2-hydroxytetradecanoylamino)dodecane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxytetradecanoylamino)dodecane-1-sulfonic acid

C26H53NO6S (507.3593)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] pentanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] pentanoate

C25H50NO7P (507.3325)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] propanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] propanoate

C25H50NO7P (507.3325)


   

3-Hydroxy-2-(2-hydroxyhexadecanoylamino)decane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxyhexadecanoylamino)decane-1-sulfonic acid

C26H53NO6S (507.3593)


   

3-Hydroxy-2-(2-hydroxydodecanoylamino)tetradecane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxydodecanoylamino)tetradecane-1-sulfonic acid

C26H53NO6S (507.3593)


   

[2-acetyloxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-acetyloxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C25H50NO7P (507.3325)


   

Cer 18:3;3O/12:1;(2OH)

Cer 18:3;3O/12:1;(2OH)

C30H53NO5 (507.3924)


   
   

[2-propanoyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-propanoyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C25H50NO7P (507.3325)


   

4-[3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

4-[3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C28H45NO7 (507.3196)


   

N-(decanoyl)-hexadecasphinganine-1-phosphate

N-(decanoyl)-hexadecasphinganine-1-phosphate

C26H54NO6P (507.3689)


   

N-(dodecanoyl)-tetradecasphinganine-1-phosphate

N-(dodecanoyl)-tetradecasphinganine-1-phosphate

C26H54NO6P (507.3689)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] butanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] butanoate

C25H50NO7P (507.3325)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] hexanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] hexanoate

C25H50NO7P (507.3325)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] acetate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] acetate

C25H50NO7P (507.3325)


   

lysoDGTS 19:4

lysoDGTS 19:4

C29H49NO6 (507.356)


   

LysoPC(17:1/0:0)

[(2R)-3-[(Z)-heptadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C25H50NO7P (507.3325)


   

2-[[(E)-2-acetamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-acetamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-icos-11-enoate

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-icos-11-enoate

C25H50NO7P (507.3325)


   

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-icos-13-enoate

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-icos-13-enoate

C25H50NO7P (507.3325)


   

2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)dodec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)dodec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[[(E)-2-(dodecanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(dodecanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[[(E)-2-(decanoylamino)-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(decanoylamino)-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[[(E)-2-(butanoylamino)-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(butanoylamino)-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[[(E)-2-(heptanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(heptanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   

2-[[(E)-2-(hexanoylamino)-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(hexanoylamino)-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H52N2O6P+ (507.3563)


   
   

1-(1Z-octadecenyl)-sn-glycero-3-phosphocholine

1-(1Z-octadecenyl)-sn-glycero-3-phosphocholine

C26H54NO6P (507.3689)


   

LysoPE(0:0/20:1(11Z))

LysoPE(0:0/20:1(11Z))

C25H50NO7P (507.3325)


   

1-(11Z-eicosenoyl)-glycero-3-phosphoethanolamine

1-(11Z-eicosenoyl)-glycero-3-phosphoethanolamine

C25H50NO7P (507.3325)


   

1-[(11Z)-octadecenyl]-sn-glycero-3-phosphocholine

1-[(11Z)-octadecenyl]-sn-glycero-3-phosphocholine

C26H54NO6P (507.3689)


A 1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as (11Z)-octadecenyl.

   

1-oleyl-sn-glycero-3-phosphocholine

1-oleyl-sn-glycero-3-phosphocholine

C26H54NO6P (507.3689)


A 1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as oleyl (9Z-octadecenyl).

   

1-(10Z-heptadecenoyl)-sn-glycero-3-phosphocholine

1-(10Z-heptadecenoyl)-sn-glycero-3-phosphocholine

C25H50NO7P (507.3325)


A 1-O-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group is (10Z)-heptadecenoyl.

   

1-(9Z-heptadecenoyl)-glycero-3-phosphocholine

1-(9Z-heptadecenoyl)-glycero-3-phosphocholine

C25H50NO7P (507.3325)


   

lysophosphatidylcholine O-18:1

lysophosphatidylcholine O-18:1

C26H54NO6P (507.3689)


A monoalkylglycerophosphocholine in which the alkyl group contains 18 carbons and one double bond. If R1 is an alkenyl group and R2 is a hydrogen then the molecule is a 1-alkenyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is an alkenyl group then the molecule is a 2-alkenyl-sn-glycero-3-phosphocholine.

   

lysophosphatidylcholine 17:1

lysophosphatidylcholine 17:1

C25H50NO7P (507.3325)


A lysophosphatidylcholine in which the remaining acyl group contains 17 carbons and 1 double bond. If R1 is acyl and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is acyl then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.

   

lysophosphatidylcholine O-18:1/0:0

lysophosphatidylcholine O-18:1/0:0

C26H54NO6P (507.3689)


A lysophosphatidylcholine O-18:1 in which the alkyl group is located at position 1.

   

lysophosphatidylethanolamine 20:1

lysophosphatidylethanolamine 20:1

C25H50NO7P (507.3325)


A lysophosphatidylethanolamine in which the acyl group (position not specified) contains 20 carbons and 1 double bond.

   

LdMePE(18:1)

LdMePE(18:1)

C25H50NO7P (507.3325)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

MePC(16:1)

MePC(8:1(1)_8:0)

C25H50NO7P (507.3325)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

BisMePE(18:1)

BisMePE(8:1(1)_10:0)

C25H50NO7P (507.3325)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   

LPC P-18:0 or LPC O-18:1

LPC P-18:0 or LPC O-18:1

C26H54NO6P (507.3689)


   
   
   

PC P-17:0 or PC O-17:1

PC P-17:0 or PC O-17:1

C25H50NO7P (507.3325)


   
   
   
   
   
   
   

PE P-16:0/4:0 or PE O-16:1/4:0

PE P-16:0/4:0 or PE O-16:1/4:0

C25H50NO7P (507.3325)


   
   

PE P-18:0/2:0 or PE O-18:1/2:0

PE P-18:0/2:0 or PE O-18:1/2:0

C25H50NO7P (507.3325)


   
   

PE P-20:0 or PE O-20:1

PE P-20:0 or PE O-20:1

C25H50NO7P (507.3325)


   

Cer 14:2;O3/16:2;O

Cer 14:2;O3/16:2;O

C30H53NO5 (507.3924)


   

CerP 14:0;O2/12:0

CerP 14:0;O2/12:0

C26H54NO6P (507.3689)


   

CerP 14:1;O2/11:0;O

CerP 14:1;O2/11:0;O

C25H50NO7P (507.3325)


   

CerP 15:0;O2/11:0

CerP 15:0;O2/11:0

C26H54NO6P (507.3689)


   

CerP 15:1;O2/10:0;O

CerP 15:1;O2/10:0;O

C25H50NO7P (507.3325)


   

CerP 16:0;O2/10:0

CerP 16:0;O2/10:0

C26H54NO6P (507.3689)


   
   
   
   
   
   
   
   
   
   
   

Val-alphaMCA

Val-alphaMCA

C29H49NO6 (507.356)


   

Val-betaMCA

Val-betaMCA

C29H49NO6 (507.356)


   
   
   

ST 26:2;O5;Gly

ST 26:2;O5;Gly

C28H45NO7 (507.3196)


   

ST 27:1;O4;Gly

ST 27:1;O4;Gly

C29H49NO6 (507.356)


   

ST 28:0;O3;Gly

ST 28:0;O3;Gly

C30H53NO5 (507.3924)


   

ST 20:1;O2;HexNAc

ST 20:1;O2;HexNAc

C28H45NO7 (507.3196)


   

ST 21:0;O;HexNAc

ST 21:0;O;HexNAc

C29H49NO6 (507.356)


   

(2-{[(2r)-2-hydroxy-3-[(4z)-octadec-4-en-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-[(4z)-octadec-4-en-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


   

n-[(2s,3r,4r,5s,6r)-2-{[(1s,2s,4ar,4bs,7s,10ar)-7-ethenyl-2-hydroxy-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2h-phenanthren-1-yl]methoxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(2s,3r,4r,5s,6r)-2-{[(1s,2s,4ar,4bs,7s,10ar)-7-ethenyl-2-hydroxy-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2h-phenanthren-1-yl]methoxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C28H45NO7 (507.3196)


   

(2-{[(2r)-2-hydroxy-3-(octadec-11-en-1-yloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-(octadec-11-en-1-yloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


   

n-{2-[(7-ethenyl-2-hydroxy-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2h-phenanthren-1-yl)methoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}ethanimidic acid

n-{2-[(7-ethenyl-2-hydroxy-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2h-phenanthren-1-yl)methoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}ethanimidic acid

C28H45NO7 (507.3196)


   

(2-{[(2r)-2-hydroxy-3-(octadec-4-en-1-yloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-(octadec-4-en-1-yloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


   

(2-{[(2r)-2-hydroxy-3-[(11z)-octadec-11-en-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-[(11z)-octadec-11-en-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


   

(2e,4e,6e,8e)-9-[(2r,3r)-3-[(2s,3r,4e,6s)-3-hydroxy-4,6-dimethyl-8-phenyloct-4-en-2-yl]-2-methyloxiran-2-yl]-n-[(2s)-1-hydroxypropan-2-yl]-2-methylnona-2,4,6,8-tetraenimidic acid

(2e,4e,6e,8e)-9-[(2r,3r)-3-[(2s,3r,4e,6s)-3-hydroxy-4,6-dimethyl-8-phenyloct-4-en-2-yl]-2-methyloxiran-2-yl]-n-[(2s)-1-hydroxypropan-2-yl]-2-methylnona-2,4,6,8-tetraenimidic acid

C32H45NO4 (507.3348)


   

(2e,4e,6e,8e)-9-{3-[(2s,3r,4e,6s)-3-hydroxy-4,6-dimethyl-8-phenyloct-4-en-2-yl]-2-methyloxiran-2-yl}-n-[(2s)-1-hydroxypropan-2-yl]-2-methylnona-2,4,6,8-tetraenimidic acid

(2e,4e,6e,8e)-9-{3-[(2s,3r,4e,6s)-3-hydroxy-4,6-dimethyl-8-phenyloct-4-en-2-yl]-2-methyloxiran-2-yl}-n-[(2s)-1-hydroxypropan-2-yl]-2-methylnona-2,4,6,8-tetraenimidic acid

C32H45NO4 (507.3348)


   

(11z,13e)-6-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-5,7,9,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

(11z,13e)-6-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-5,7,9,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

C29H49NO6 (507.356)


   

methyl (2s)-1-{[(3r,4s,5r)-5-[(6e)-heptadec-6-en-1-yl]-4-hydroxy-5-methyl-2-oxooxolan-3-yl]methyl}-5-oxopyrrolidine-2-carboxylate

methyl (2s)-1-{[(3r,4s,5r)-5-[(6e)-heptadec-6-en-1-yl]-4-hydroxy-5-methyl-2-oxooxolan-3-yl]methyl}-5-oxopyrrolidine-2-carboxylate

C29H49NO6 (507.356)


   

(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 2-methylpropanoate

(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 2-methylpropanoate

C28H45NO7 (507.3196)


   

methyl 1-{[5-(heptadec-6-en-1-yl)-4-hydroxy-5-methyl-2-oxooxolan-3-yl]methyl}-5-oxopyrrolidine-2-carboxylate

methyl 1-{[5-(heptadec-6-en-1-yl)-4-hydroxy-5-methyl-2-oxooxolan-3-yl]methyl}-5-oxopyrrolidine-2-carboxylate

C29H49NO6 (507.356)


   

(2-{[(2r)-2-hydroxy-3-[(3z)-octadec-3-en-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-[(3z)-octadec-3-en-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


   

9-[3-(3-hydroxy-4,6-dimethyl-8-phenyloct-4-en-2-yl)-2-methyloxiran-2-yl]-n-(1-hydroxypropan-2-yl)-2-methylnona-2,4,6,8-tetraenamide

9-[3-(3-hydroxy-4,6-dimethyl-8-phenyloct-4-en-2-yl)-2-methyloxiran-2-yl]-n-(1-hydroxypropan-2-yl)-2-methylnona-2,4,6,8-tetraenamide

C32H45NO4 (507.3348)


   

methyl (2r)-1-{[(3s,4s,5r)-5-[(6e)-heptadec-6-en-1-yl]-4-hydroxy-5-methyl-2-oxooxolan-3-yl]methyl}-5-oxopyrrolidine-2-carboxylate

methyl (2r)-1-{[(3s,4s,5r)-5-[(6e)-heptadec-6-en-1-yl]-4-hydroxy-5-methyl-2-oxooxolan-3-yl]methyl}-5-oxopyrrolidine-2-carboxylate

C29H49NO6 (507.356)


   

(5s)-5-[(1s,2e,9r,16s,17e,19s,22s,24r)-19-hydroxy-2,15,18,24-tetramethyl-25-oxa-5-azatetracyclo[20.2.1.0⁴,⁹.0¹¹,¹⁶]pentacosa-2,4,14,17-tetraen-14-yl]-3-methyl-5h-furan-2-one

(5s)-5-[(1s,2e,9r,16s,17e,19s,22s,24r)-19-hydroxy-2,15,18,24-tetramethyl-25-oxa-5-azatetracyclo[20.2.1.0⁴,⁹.0¹¹,¹⁶]pentacosa-2,4,14,17-tetraen-14-yl]-3-methyl-5h-furan-2-one

C32H45NO4 (507.3348)


   

(2-{[(2r)-2-hydroxy-3-(octadec-3-en-1-yloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-(octadec-3-en-1-yloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

C26H54NO6P (507.3689)


   

11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 2-methylpropanoate

11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 2-methylpropanoate

C28H45NO7 (507.3196)